Perspective Therapeutics Announces Voting Results

SEATTLE, Perspective Therapeutics, Inc. (NYSE American:CATX), a $190 million market cap company currently trading at $2.57, disclosed the outcomes of its 2025 Annual Meeting of Stockholders held on May 28, 2025. According to InvestingPro data, the company has experienced significant market challenges, with its stock price declining over 83% in the past year. A quorum was reached with 82.17% of shares represented, and the following key decisions were made:

Proposal 1, the Election Proposal, resulted in the election of five board members, Lori A. Woods, Heidi Henson, Frank Morich, M.D., Ph.D., Johan (Thijs) Spoor, and Robert Froman Williamson, III, to serve until the 2026 Annual Meeting. Votes for each nominee varied, with Lori A. Woods receiving the highest number of "for" votes at 48,265,909 and Heidi Henson following with 41,847,883.

Proposal 2, the Auditor Ratification Proposal, saw the ratification of WithumSmith+Brown, PC as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, with an overwhelming majority of 59,126,140 votes in favor.

Proposal 3, the Say on Pay Proposal, was approved on an advisory basis, with 38,730,185 votes for the compensation of the company’s named executive officers as disclosed in the proxy statement.

The results reflect the shareholders’ support for the current board’s composition and the company’s executive compensation practices. The ratification of the accounting firm also indicates shareholder confidence in the company’s financial auditing process.

This report is based on a press release statement and provides a summary of the key decisions made at Perspective Therapeutics, Inc.’s Annual Meeting.

In other recent news, Perspective Therapeutics Inc has been in the spotlight with several key developments. The company reported its first-quarter results, leading Oppenheimer to adjust their price target from $16 to $15, while maintaining an Outperform rating. Perspective Therapeutics ended the first quarter with $212 million in cash, expected to fund operations into late 2026. Truist Securities also revised its outlook, cutting the price target from $21 to $10, but maintained a Buy rating. This adjustment followed the company’s fourth-quarter 2024 results and changes in commercialization timelines due to dose escalation trials.

Additionally, Oppenheimer had earlier maintained their Outperform rating with a $16 target, reflecting confidence in Perspective Therapeutics’ financial stability and ongoing clinical trials. Scotiabank (TSX:BNS) initiated coverage on the company with a Sector Outperform rating and a $15 price target, citing the company’s potential and its status as a leading independent radiopharmaceutical entity. Scotiabank’s analysis highlighted the promise in Perspective’s melanoma, FAP-alpha, and pre-targeting platform programs. These developments indicate a continued interest and varied perspectives from analysts on the company’s future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.